Pharmacology
-
Biologic treatment expansion leads to population-level reductions in asthma exacerbations
Findings show that beginning in 2015, annual exacerbation events decreased by 474.1 events per 1,000 patients per year and have continued to decline by 206.5 events per 1,000 patients per year.
-
FDA approval of oveporexton for narcolepsy allows clinicians to treat more than symptoms
When the US Food and Drug Administration approved the drug in August, oveporexton became the first agent to target the loss of orexin signaling that causes narcolepsy type 1.
-
Selpercatinib improves event-free survival in early-stage RET fusion-positive NSCLC
Alexander E. Drilon, MD, discusses the findings from the first randomized phase 3 trial to evaluate a RET kinase inhibitor as adjuvant therapy in RET fusion-positive lung cancer.
-
Limited data on GLP-1RAs show early promise in PAH
A review led by Benoît Aguado, MD, explores several mechanisms that could make GLP-1 receptors relevant to pulmonary vascular disease.
-
When PH and ILD meet: From overlap to a unified disease paradigm
For clinicians, the shift in the PH-ILD space demands a broader perspective that integrates vascular and parenchymal disease, emphasizes early detection, and prioritizes multidisciplinary care.
-
Evolving biologic treatment options improving outcomes for patients with COPD
Farrukh Abbas, MD, FCCP, and Nicola Alexander Hanania, MD, MS, FCCP, explore the various treatment pathways—and the drugs targeting them—with the potential to reduce COPD exacerbations.
-
Varenicline sampling with minimal guidance may boost smoking cessation rates
According to the investigators, the medication sampling model may lower barriers to engagement and allow patients to consider cessation on their own terms.
-
Short-course all-oral therapy appears effective, safe for resistant TB
Patrick PJ Phillips, PhD, said the noninferiority BEAT Tuberculosis trial showed a six-month treatment strategy could achieve outcomes similar to those of longer, standard regimens.
-
Ensitrelvir cuts COVID-19 risk by two-thirds after household exposure
Paul E. Sax, MD, said postexposure prophylaxis may be a useful addition to vaccination, testing, and treatment, particularly in populations at high-risk of severe disease.
-
Study evaluates amivantamab plus lazertinib for EGFR-mutant NSCLC with CNS metastases
With the combination now available, Mark Jeng, MD, PhD, revisits positive results from a recent study evaluating the strategy in this high-risk population.
